Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

PATH

Status and phase: Completed; Phase 1

Conditions: Influenza; Vaccine

Treatments: Biological: Phosphate buffered saline (PBS); Biological: cH8/1N1 LAIV; Biological: cH5/1N1 IIV; Biological: AS03-adjuvanted cH8/1N1 IIV; Biological: Normal saline; Biological: AS03-adjuvanted cH5/1N1 IIV

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03300050

CVIA 057 (1082166-1)

Details and patient eligibility

About

The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.

Full description

This is a prospective, multi-center, randomized, controlled, observer-blind, Phase 1 trial in healthy male and female adults 18 through 39 years of age to evaluate safety and the immune response of a prime boost regimen with LAIV prime and IIV boost with or without adjuvant. Participants will be randomized 4:3:1:3:2 to one of five groups to receive a first dose of study cH8/1N1 LAIV (or placebo) or study cH8/1N1 IIV + AS03A adjuvant (or placebo) followed three months later by study cH5/1N1 IIV +/- AS03A adjuvant (or placebo).

Enrollment: 65 patients

Sex: All

Ages: 18 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of study by passing a written examination prior to vaccination.
• In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
• Written informed consent obtained from the subject prior to performance of any study specific procedure.
• Male or non-pregnant female between, and including, 18 and 39 years of age at the time of the first vaccination.
• Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality*.
• Female subjects of non-childbearing potential may be enrolled in the study.
• Female subjects of childbearing potential must have a negative pregnancy test within 24 hours of vaccination.
• Female subjects of childbearing potential must have practiced adequate contraception for 30 days prior to first vaccination and agree to continue adequate contraception until 2 months after completion of the vaccination series (Month 5).
• Male subjects must be surgically sterile (e.g., vasectomy) or agree to practice adequate contraception from the first vaccination until 2 months after completion of the vaccination series (Month 5). Please refer to the glossary of terms for the definition of adequate contraception.

Exclusion criteria

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines.
• Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
• Medically diagnosed deviated nasal septum or nasal obstruction.
• Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within 6 months before the first dose.
• Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months before the first dose (Visit 03), or planned administration any time during the study period.
• Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose (Visit 03) up to Month 15 (Visit 15)
• Persons who should be annually vaccinated against influenza who live with or care for persons at high risk for influenza-related complications.
• History of influenza vaccination within 6 months prior to study enrollment or unwillingness to forego seasonal influenza vaccination during the entire study period.
• History of vaccination with an investigational pandemic influenza vaccine other than an 2009 H1N1 Pandemic (H1N1pdm09) vaccine.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• Infection with human immunodeficiency virus regardless of clinical stage of immunodeficiency.
• History of current infection with hepatitis B virus or hepatitis C virus regardless of clinical presentation.
• History of or current autoimmune disease.
• Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling.
• History of Guillain-Barré syndrome.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including egg proteins); a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
• Hypersensitivity to latex.
• Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.
• Pregnant or lactating female.
• Female planning to become pregnant or male planning to father a child or either planning to discontinue contraceptive precautions.
• Current smoker.
• During screening, have a positive test for opiates without a prescription.
• History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
• Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.
• Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with subject compliance or safety evaluations.
• Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 10 years prior to study vaccination.
• Blood donation or planned blood donation within 30 days prior to the study vaccination through 30 days after the last blood drawn for this study.
• Have signs or symptoms that could confound or confuse assessment of study vaccine reactogenicity.
• Any hematological or biochemical parameter that is out of range of normal, and is considered clinically significant by the investigator.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

65 participants in 5 patient groups, including a placebo group

Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant

Experimental group

Description:

Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.

Treatment:

Biological: AS03-adjuvanted cH5/1N1 IIV

Biological: cH8/1N1 LAIV

Group 2: cH8/1N1 LAIV and cH5/1N1 IIV

Experimental group

Description:

Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.

Treatment:

Biological: cH8/1N1 LAIV

Biological: cH5/1N1 IIV

Group 3: Placebo

Placebo Comparator group

Description:

Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.

Treatment:

Biological: Normal saline

Biological: Phosphate buffered saline (PBS)

Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant

Experimental group

Description:

Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.

Treatment:

Biological: AS03-adjuvanted cH5/1N1 IIV

Biological: AS03-adjuvanted cH8/1N1 IIV

Group 5: Placebo

Placebo Comparator group

Description:

Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.

Treatment:

Biological: Phosphate buffered saline (PBS)